The healthcare giant has been investing heavily in its future growth.

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while ...

Sens. Susan Collins (R-ME) and Claire McCaskill (D-MO) sent five identical letters late last week to opioid overdose antidote manufacturers Pfizer, Amphastar Pharmaceuticals, Mylan, Kaléo Pharma and ...

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The healthcare stock looks ridiculously undervalued.

Pfizer's oncology ambitions could start to take shape next year. The drugmaker is also likely to make progress in the weight-loss market. It might take a while longer, but Pfizer is on the path to ...

Pfizer is one of the world's largest pharmaceutical companies. It has a long history of navigating the competitive and technically complex industry. Pfizer's stock has lost half its value since late ...

Pharmaceutical companies AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, ...

Pfizer delivered a significant earnings surprise in its third-quarter results, demonstrating the pharmaceutical giant’s resilience amid a challenging year for its stock performance. The company’s ...